SIRT1 and metabolic syndrome: In contrast, the downregulation of SIRT1 or the inhibition of its activity has been implicated in the pathophysiology of metabolic syndrome determinants, including insulin resistance, type 2 diabetes, and liver lipid accumulation (Wang et al., 2012).